

Measles vaccines: WHO position paper – 28 April 2017
Grading of scientific evidence in support of key recommendations

Table IV: Safety of the measles vaccine in young children and adolescents

Population : Immunocompetent young children and adolescents

Intervention: Measles vaccination (any dose)

Comparison : No vaccination

Outcome : Serious adverse events related to immunization

| PICO Question: Are measles containing vaccines safe when used for preventing measles in young children and adolescents? | | | | |
|--|--|---|---|----------|
| | | Rating | Adjustment to rating | |
| Quality Assessment | No of studies/starting rating | | 46 RCTs/observational studies ¹ | 4 |
| | Factors decreasing confidence | Limitation in study design | Serious ² | -1 |
| | | Inconsistency | None serious | 0 |
| | | Indirectness | None serious | 0 |
| | | Imprecision | None serious | 0 |
| | | Publication bias | Not applicable | 0 |
| | Factors increasing confidence | Strength of association/large effect | Not applicable | 0 |
| | | Dose-response | Not applicable | 0 |
| | | Antagonistic/mitigated bias and confounding | Not applicable | 0 |
| | Final numerical rating of quality of evidence | | | 3 |
| Summary of Findings | Statement on quality of evidence | | Evidence supports a moderate level of confidence that the true effect lies close to that of the estimate of the effect on the health outcome. | |
| | Conclusion | | Measles vaccine does not cause serious adverse events (moderate level of scientific evidence). | |

¹ Two systemic reviews have been conducted that included review of measles vaccine safety and assessed the quality of evidence: an overall adverse event grading by Demicheli V et al and an event-specific grading by Elliman D et al. In a Cochrane database systematic review in 2012 based on 35 comparative prospective or retrospective trials published during the period 1985–2011, *Demicheli V et al* concluded that MMR was associated with a lower incidence of upper respiratory tract infections, a higher incidence of irritability, and a similar incidence of other adverse effects compared to placebo. The vaccine was likely to be associated with benign thrombocytopenic purpura, parotitis, joint and limb complaints, febrile convulsions within two weeks of vaccination and aseptic meningitis (mumps) using Urabe strain-containing MMR. Exposure to MMR was unlikely to be associated with Crohn’s disease, ulcerative colitis, autism or aseptic meningitis (mumps) using Jeryl-Lynn strain-containing MMR. In the systematic review by *Elliman D et al, 2007*, the grading of scientific evidence related to different types of adverse events was as follows: As compared to control groups, MCV increases the incidence of acute fever and febrile seizures (moderate evidence): (*anonymous 1968; Virtanen M et al, 2000; Barlow WE et al, 2001; Vestergaard M et al, 2004*); does not seem to increase the risk of asthma and eczema (very low evidence) : (*Maier JE et al, 2004; McKeever TM et al, 2004*); does not seem to cause aseptic meningitis (very low evidence): (*Dourado I, et al 2000; Ki M et al, 2003*); does not seem to increase the risk of development regression or autistic spectrum disorders (low evidence): (*DeStefano F et al, 2004; Madsen KM et al, 2002*); and does not seem to increase the risk of inflammatory bowel disease (*Patja A et al, 2000*).

² The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate.

References

1. Anonymous. Vaccination against measles: clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Second report to the medical research council by the measles vaccines committee. *BMJ* 1968;2:449-452.
2. Barlow WE, Davis RL, Glasser JW. The risk of seizures after receipt of whole cell pertussis or measles mumps and rubella vaccine. *N Engl J Med* 2001;345:656-661.
3. Demicheli V, Rivetti A, Debalini MG di Pietrantonj C. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev.* 2011 May Issue 2. Art. No.: CD004407..
4. De Stefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study metropolitan Atlanta. *Pediatrics* 2004;113:259-266.
5. Dourado I, Cunha S, Teixeira MG, et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. *Am J Epidemiol* 2000;151:524-530.
6. Elliman D, Sengupta N, El Bashir H, and Bedford H. Child health. Measles, mumps, and rubella prevention. *Clinical Evidence*. Web publication date: 01 Feb 2007.
http://clinicalevidence.bmj.com/ceweb/conditions/chd/0316/0316_11.jsp
7. Ki M, Park T, Yi SG, et al. Risk analysis of aseptic meningitis after measles-mumps-rubella vaccination in Korean children by using a case-crossover design. *Am J Epidemiol* 2003;157:158-165.
8. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med* 2002;347:1477-1482.
9. Maher JE, Mullooly JP, Drew L, et al. Infant vaccinations and childhood asthma among full-term infants. *Pharmacoepidemiol Drug Saf* 2004;13:1-9.
10. McKeever TM, Lewis SA, Smith C, et al. Vaccination and allergic disease: a birth cohort study. *Am J Public Health* 2004;94:985-989.
11. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen year prospective follow up. *Pediatr Infect Dis J* 2000;19:1127-1134.
12. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA* 2004;292:351-357.
13. Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. *Pediatrics* 2000;106:e62.
14. Ahlgren C, Oden A, Toren K, Andersen O. Multiple sclerosis incidence in the era of measles-mumps-rubella mass vaccinations. *Acta Neurologica Scandinavica* 2009;119 (5):313–20.
15. Ahlgren C, Toren K, Oden A, Andersen O. A population based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk. *European Journal of Epidemiology* 2009;24(9):541–52.
16. Bertuola F, Morando C, Menniti-Ippolito F, Da Cas R, Capuano A, Perilongo G, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. *Drug Safety* 2010; 33(1):65–72.
17. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. *British Journal of Clinical Pharmacology* 2003;55(1):107–11.
18. Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to twoyear- old children: an

analysis of the Vaccine Safety Datalink (VSD) Project. *Pediatric Infectious Disease Journal* 1997;**16** (5):500–3.

19. Bremner SA, Carey IM, DeWilde S, Richards N, Maier WC, Hilton SR, et al. Timing of routine immunisations and subsequent hay fever risk. *Archives of Disease in Childhood* 2005;**90**(6):567–73.
20. Bremner SA, Carey IM, DeWilde S, Richards N, Maier WC, Hilton SR, et al. Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever. *Clinical and Experimental Allergy* 2007;**37** (4):512–7.
21. da Cunha SS, Rodrigues LC, Barreto ML, Dourado I. Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain. *Vaccine* 2002;**20**(7-8):1106–12.
22. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. *Archives of Pediatric and Adolescent Medicine* 2001;**155**(3):354–9.
23. DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. *Pediatrics* 2004;**113**(2):259–66.
24. DeStefano F, Gu D, Kramarz P, Truman BI, Iademarco MF, Mullooly JP, et al. Childhood vaccinations and risk of asthma. *Pediatric Infectious Disease Journal* 2002;**21**(6): 498–504.
25. Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, et al. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measlesmumps- rubella vaccine: implications for immunization programs. *American Journal of Epidemiology* 2000;**151**(5): 524–30.
26. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. *Pediatrics* 2006;**118**(1):e139–50.
27. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. *Pediatrics* 2006;**118**(1):e139–50.
28. France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. *Pediatrics* 2008;**121**(3):e687–92.
29. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. *Journal of Child Psychology and Psychiatry, and Allied Disciplines* 2005;**46**(6):572–9.
30. Hviid A, Melbye M. Measles-mumps-rubella vaccination and asthma-like disease in early childhood. *American Journal of Epidemiology* 2008;**168**(11):1277–83.
31. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. *New England Journal of Medicine* 2004;**350**(14):1398–404.
32. Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional

- pharmacovigilance centres and Pasteur-Merieux serums et vaccins. *Pediatric Infectious Disease Journal* 1996; **15**(1):44–8.
33. Ma X, Does MB, Metayer C, Russo C, Wong A, Buffler PA. Vaccination history and risk of childhood leukaemia. *International Journal of Epidemiology* 2005;**34**(5):1100–9.
 34. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *New England Journal of Medicine* 2002;**347**(19):1477–82.
 35. Makela A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. *Pediatrics* 2002;**110** (5):957–63.
 36. McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: a birth cohort study. *American Journal of Public Health* 2004;**94**(6):985–9.
 37. Miller E, Andrews N, Grant A, Stowe J, Taylor B. No evidence of an association between MMR vaccine and gait disturbance. *Archives of Disease in Childhood* 2005;**90**(3): 292–6.
 38. Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. *American Journal of Epidemiology* 2007;**165**(6):704–9.
 39. Mrozek-Budzyn D, Kieltyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. *Pediatric Infectious Disease Journal* 2010;**29**(5):397–400.
 40. Park T, Ki M, Yi SG. Statistical analysis of MMR vaccine adverse events on aseptic meningitis using the case crossover design. *Statistics in Medicine* 2004;**23**(12):1871–83.
 41. Ray P, Hayward J, Michelson D, Lewis E, Schwalbe J, Black S, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. *Pediatric Infectious Disease Journal* 2006;**25**(9):768–73.
 42. Seagroatt V. MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. *BMJ* 2005;**330**(7500):1120–1.
 43. Smeeth L, Cook C, Fombonne E, Heavey L, Rodrigues LC, Smith PG, et al. MMR vaccination and pervasive developmental disorders: a case-control study. *Lancet* 2004; **364**(9438):963–9.
 44. Stowe J, Andrews N, Taylor B, Miller E. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. *Vaccine* 2009;**27**(9):1422–5.
 45. Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot- Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet* 1999;**353**(9169):2026–9.
 46. Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. *Journal of Autism and Developmental Disorders* 2007;**37**(2):210–7.
 47. Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. *JAMA* 2004;**292**(3):351–7.
 48. Ward KN, Bryant NJ, Andrews NJ, Bowley JS, Ohrling A, Verity CM, et al. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. *Pediatrics* 2007;**120**(2):314–21.